In response to Focosi and Casadevall.

Antibody profiles in COVID-19 convalescent plasma prepared with amotosalen/ UVA pathogen reduction treatment. In view of our observations that antibody to the N antigen was retained after pathogen reduction we are optimistic that the Fc functionality is retained in Amotosalen/UVA pathogen reduced CCP. The letter of Focosi and Casadevall raises the interesting question of the functionality of the Fc portion of antibodies to SARS-CoV-2 in pathogen reduced COVID convalescent plasma (CCP) with reference to our study of CCP antibody profiles.1 They note that antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) may be important for the clearance of SARS-CoV-2 in infected patients and for disease resolution. [Extracted from the article]